3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
5
Neoplasms
4
Small Cell Lung Carcinoma
2
Squamous Cell Carcinoma of Head and Neck
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Infections
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
COVID-19
1
Breast Neoplasms
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
Voriconazole
2
Caspofungin
2
telavancin
1
monalizumab
1
fludarabine phosphate
1
fish oil triglycerides
1
avdoralimab
1
Whole-Body Irradiation
1
Trimethoprim, Sulfamethoxazole Drug Combination
1
Therapeutics
1
Tacrolimus
1
Standard of Care
1
Sirolimus
1
Peripheral Blood Stem Cell Transplantation
1
Observation
1
Methotrexate
1
Melphalan
1
Interferon-gamma
1
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
1
Hematopoietic Stem Cell Transplantation
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Etoposide
1
Daptomycin
1
Cyclophosphamide
1
Clarithromycin
1
Bevacizumab
1
Antilymphocyte Serum
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Infections
×
monalizumab
×
Clear all
NCT04333914
2022-09-30
IMMUNONCOVID
Centre Leon Berard
Phase 2
Completed
19 enrolled